Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Policies & Guidelines
Filter by Topic
Best Practices
Clinical Guidelines
End-of-Life Care
Health Policy
NCCN 2015 Updates
NCCN Guidelines
Pathways
Patient Advocacy
Patient Navigation
Quality Care
Survivorship
Survivorship Care
Understanding the Preventive Services Rule Changes
Health Policy
,
Policies & Guidelines
September 2010, Vol 1, No 4
On July 14, 2010, the Departments of Treasury, Labor, and Health and Human Services issued interim final rules for group health plans and health insurance issuers to provide detail on how those entities are to cover the preventive services required under the Patient Protection and Affordable Care Act (PPACA).
Read Article
REMS Regulation Provokes Anger in Provider Community
Health Policy
,
Policies & Guidelines
September 2010, Vol 1, No 4
Silver Spring, MD—Risk Evaluation and Mitigation Strategies (REMS) are required from some drug manufacturers as part of a new US Food and Drug Administration (FDA) regulation designed to draw the attention of sponsors, providers, and patients to the likelihood of severe adverse events accompanying certain drugs and biologic agents.
Read Article
Identifying Long-Term Unmet Needs in Survivorship Care
By
Meg Barbor, MPH
Survivorship
,
Policies & Guidelines
December 2017, Vol 8, No 5
New Orleans, LA—The number of cancer survivors is increasing. To keep up with this trend, survivorship care must evolve and become more efficient, insists Jennifer R. Klemp, PhD, MPH, MA, Director, Cancer Survivorship, University of Kansas Cancer Center, Westwood. A growing number of patients are living with or through their disease, while the provider workforce is shrinking.
Read Article
Updated NCCN Guideline for Neuroendocrine Tumors and Carcinoid Syndrome Features New Therapies
By
Wayne Kuznar
NCCN Conference Highlights
,
NCCN Guidelines
,
Policies & Guidelines
June 2017, Vol 8, No 3
Orlando, FL—Somatostatin analogs have multiple roles in the treatment of neuroendocrine tumors (NETs), including the management of symptoms of hormone hypersecretion and, more recently, slowing tumor progression.
Read Article
Navigating Patient Assistance Programs
By
Jessica Miller
Patient Navigation
,
Patient Support Services
,
Policies & Guidelines
December 2016, Vol 7, No 11
Washington, DC—In the past 6 years, more than $4 billion in charitable assistance has been dedicated to patients in need. In 2015 alone, the Patient Access Network (PAN) Foundation provided $950 million in cancer care support. The only people with deep enough pockets to support this type of assistance are drug manufacturers, adding to an already complicated regulatory environment for charitable assistance programs, said Daniel J. Klein, President and Chief Executive Officer, PAN Foundation, at the Sixth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
The Impact of Policy and Politics on Health and Drug Pricing
By
Jessica Miller
Health Policy
,
Policies & Guidelines
December 2016, Vol 7, No 11
Washington, DC—A panel discussion on health and drug politics took place at the Sixth Annual Conference of the Association for Value-Based Cancer Care. The expert panel included Kavita Patel, MD, Johns Hopkins Medicine, Baltimore; Dan Todd, Principal of Todd Strategy, Washington, DC; and Liz Fowler, Vice President, Global Health Policy, Johnson & Johnson. The panel discussed what is working in healthcare, what is not, and where cancer care fits into it all.
Read Article
Is Direct-to-Consumer Advertising for Cancer Drugs Beneficial to Patients?
By
Jessica Miller
Health Policy
,
Policies & Guidelines
October 2016, Vol 7, No 9
Read Article
Many Cancer Survivors Have Untreated Depression
By
Charles Bankhead
Survivorship
,
Policies & Guidelines
October 2016, Vol 7, No 9
Read Article
Patient Relationship Management: Novel Software for a New Era of Patient Navigation in Oncology
Patient Navigation
,
Policies & Guidelines
October 2016, Vol 7, No 9
As cancer care providers well know, the landscape of healthcare delivery is changing in complex and dramatic ways. Two related trends are driving this change: the shift among payers to value-based reimbursement, and rapidly evolving patient expectations.
Read Article
Increase in Drug Spending Largely Attributed to Rebates Pocketed by Pharmacy Benefit Managers
By
Robert Goldberg, PhD
Patient Advocacy
,
Policies & Guidelines
September 2016, Vol 7, No 8
Total drug spending in the United States, based on invoice prices, reached $425 billion in 2015, according to the IMS Institute for Healthcare Informatics report, “Medicines Use and Spending in the U.S.: A Review of 2015 and Outlook to 2020.” When adjusted for net price spending, $310 billion went to drug and biotech companies, but where the other $115 billion went is often omitted from media coverage.
Read Article
Page 1 of 11
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma